CN102724996A - 血管内皮生长因子(vegf)受体的抑制剂及其使用方法 - Google Patents

血管内皮生长因子(vegf)受体的抑制剂及其使用方法 Download PDF

Info

Publication number
CN102724996A
CN102724996A CN2010800599677A CN201080059967A CN102724996A CN 102724996 A CN102724996 A CN 102724996A CN 2010800599677 A CN2010800599677 A CN 2010800599677A CN 201080059967 A CN201080059967 A CN 201080059967A CN 102724996 A CN102724996 A CN 102724996A
Authority
CN
China
Prior art keywords
moiety
amino acid
vegf receptor
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800599677A
Other languages
English (en)
Chinese (zh)
Inventor
J·施勒辛格
杨艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN102724996A publication Critical patent/CN102724996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
CN2010800599677A 2009-12-29 2010-12-20 血管内皮生长因子(vegf)受体的抑制剂及其使用方法 Pending CN102724996A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29078909P 2009-12-29 2009-12-29
US61/290,789 2009-12-29
PCT/US2010/061296 WO2011090648A2 (en) 2009-12-29 2010-12-20 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN102724996A true CN102724996A (zh) 2012-10-10

Family

ID=44307462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800599677A Pending CN102724996A (zh) 2009-12-29 2010-12-20 血管内皮生长因子(vegf)受体的抑制剂及其使用方法

Country Status (14)

Country Link
US (1) US20130071397A1 (https=)
EP (1) EP2519253A4 (https=)
JP (1) JP2013515776A (https=)
KR (1) KR20120115348A (https=)
CN (1) CN102724996A (https=)
AU (1) AU2010343193A1 (https=)
BR (1) BR112012016309A2 (https=)
CA (1) CA2785723A1 (https=)
IL (1) IL220147A0 (https=)
IN (1) IN2012DN05014A (https=)
MX (1) MX2012007745A (https=)
RU (1) RU2012132470A (https=)
SG (1) SG181495A1 (https=)
WO (1) WO2011090648A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356226A (zh) * 2014-11-04 2015-02-18 深圳市海兰深生物医学技术有限公司 一种检测血浆免疫标志物-vegfr1自身抗体的抗原多肽及应用
CN105820244A (zh) * 2015-01-06 2016-08-03 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148134A (zh) * 2015-01-06 2018-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN109476746A (zh) * 2016-07-19 2019-03-15 F星贝塔有限公司 Egfr结合分子

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
EP3062740A4 (en) * 2013-11-01 2017-08-02 Atrium Medical Corporation Positioning agent and method of using the same
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3624811A4 (en) 2017-05-19 2021-03-10 The Regents of The University of California ANTIBODY-BASED CHEMICAL INDUCED DIMERIZER (ABCID) AS A MOLECULAR SWITCH FOR REGULATING CELL THERAPIES
EP3642225A1 (en) 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
WO2024155689A1 (en) * 2023-01-17 2024-07-25 Yale University Compounds and methods for inhibiting type-iii receptor tyrosine kinases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004066A1 (en) * 1994-02-10 2005-01-06 Patricia Rockwell Monoclonal antibodies specific to VEGF receptors and uses thereof
WO2008153926A2 (en) * 2007-06-05 2008-12-18 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1916001T1 (sl) * 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004066A1 (en) * 1994-02-10 2005-01-06 Patricia Rockwell Monoclonal antibodies specific to VEGF receptors and uses thereof
WO2008153926A2 (en) * 2007-06-05 2008-12-18 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356226A (zh) * 2014-11-04 2015-02-18 深圳市海兰深生物医学技术有限公司 一种检测血浆免疫标志物-vegfr1自身抗体的抗原多肽及应用
WO2016070662A1 (zh) * 2014-11-04 2016-05-12 青岛海兰深生物科技有限公司 一种检测血浆免疫标志物-vegfr1自身抗体的抗原多肽及应用
KR101976297B1 (ko) 2014-11-04 2019-05-07 칭다오 하일란쉔 바이오테크놀로지 컴퍼니 리미티드 혈장 면역 표지물-vegfr1 자가 항체를 검출하기 위한 항원 폴리펩티드 및 용도
KR20170082152A (ko) * 2014-11-04 2017-07-13 칭다오 하일란쉔 바이오테크놀로지 컴퍼니 리미티드 혈장 면역 표지물-vegfr1 자가 항체를 검출하기 위한 항원 폴리펩티드 및 용도
CN108285484A (zh) * 2015-01-06 2018-07-17 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148134A (zh) * 2015-01-06 2018-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148135A (zh) * 2015-01-06 2018-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148136A (zh) * 2015-01-06 2018-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN105820244B (zh) * 2015-01-06 2018-03-13 珠海亿胜生物制药有限公司 抗vegf抗体
CN105820244A (zh) * 2015-01-06 2016-08-03 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148134B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148136B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108285484B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148135B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN109476746A (zh) * 2016-07-19 2019-03-15 F星贝塔有限公司 Egfr结合分子
CN109476746B (zh) * 2016-07-19 2024-05-24 F-星治疗有限公司 Egfr结合分子

Also Published As

Publication number Publication date
MX2012007745A (es) 2012-11-23
IN2012DN05014A (https=) 2015-10-02
EP2519253A2 (en) 2012-11-07
WO2011090648A2 (en) 2011-07-28
US20130071397A1 (en) 2013-03-21
WO2011090648A3 (en) 2012-01-05
KR20120115348A (ko) 2012-10-17
SG181495A1 (en) 2012-07-30
IL220147A0 (en) 2012-07-31
AU2010343193A1 (en) 2012-06-21
JP2013515776A (ja) 2013-05-09
BR112012016309A2 (pt) 2017-04-18
EP2519253A4 (en) 2013-08-07
CA2785723A1 (en) 2011-07-28
RU2012132470A (ru) 2014-02-10

Similar Documents

Publication Publication Date Title
CN101801407B (zh) 受体酪氨酸激酶抑制剂及其使用方法
CN102724996A (zh) 血管内皮生长因子(vegf)受体的抑制剂及其使用方法
US20120328599A1 (en) Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
JP6979971B2 (ja) 抗ｐｄ−ｌ１抗体
JP2022104961A (ja) 抗ｃｄ７３抗体を用いた併用療法
KR102218497B1 (ko) 표피 성장 인자 수용체 3 (her3)에 대한 항체
TW201932493A (zh) 不致顯著紅血球凝集的抗－ｃｄ４７抗體
CN104185681A (zh) C1orf32抗体及其用于治疗癌症的用途
CN105101997A (zh) 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
JP7339159B2 (ja) 心疾患の予防および治療方法
JP2023502725A (ja) Ｔｉｅ－２に対する抗体および使用方法
CN119161478A (zh) α5β1整合素结合剂及其用途
AU2014203645A1 (en) Inhibitors of receptor tyrosine kinases and methods of use thereof
HK1196386A (en) Inhibitors of receptor tyrosine kinases and methods of use thereof
EP3145545B1 (en) Bak binding proteins
WO2011140295A2 (en) Modulators of notch receptor signaling and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121010